Blood pressure effects of the angiotensin II receptor blocker, losartan.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Archives of Internal Medicine

• Publication date

  1995-02-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHINTE.1995.00430040081010PMID 7848024
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects

  2004cited by this paper
• Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents.

  1993cited by this paper
• Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.

  1993cited by this paper
• Effect of Blocking Angiotensin II Receptor Subtype on Rat Sympathetic Nerve Function

  1992cited by this paper
• Central DuP 753 Does Not Lower Blood Pressure in Spontaneously Hypertensive Rats

  1992cited by this paper
• Circulatory and extracirculatory effects of angiotensin-converting enzyme inhibition.

  1992cited by this paper
• Role of angiotensin subtype 2 receptor in neointima formation after vascular injury.

  1992cited by this paper
• Clinical experience with angiotensin II receptor antagonists.

  1992cited by this paper
• Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report.

  1992cited by this paper
• Angiotensin II receptor subtypes.

  1992cited by this paper
• The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism.

  1992cited by this paper
• Losartan potassium, a nonpeptide antagonist of angiotensin II, chronically administered p.o. does not readily cross the blood-brain barrier.

  1992cited by this paper
• Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist

  1992cited by this paper
• Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries.

  1991cited by this paper
• Ambulatory blood pressure monitoring in the evaluation of drug efficacy.

  1991cited by this paper
• Characterization of angiotensin receptors mediating prostaglandin synthesis in C6 glioma cells.

  1991cited by this paper
• Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.

  1990cited by this paper
• Assessment of renin dependency of hypertension with a dipeptide renin inhibitor.

  1990cited by this paper
• The use of ambulatory blood pressure monitoring to improve the accuracy and reduce the numbers of subjects in clinical trials of antihypertensive agents.

  1988cited by this paper
• How common is white coat hypertension?

  1988cited by this paper
• Characterization of antihypertensive therapy by whole-day blood pressure monitoring.

  1988cited by this paper
• Assessment of patients with office hypertension by 24-hour noninvasive ambulatory blood pressure monitoring.

  1986cited by this paper
• Automated ambulatory blood pressure monitoring: a study in age-matched normotensive and hypertensive men.

  1985cited by this paper
• Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients.

  1985cited by this paper
• Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients.

  1976cited by this paper
• Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases.

  1972cited by this paper

• TGFβ in pancreas and colorectal cancer: opportunities to overcome therapeutic resistance.

  2024cites this paper
• Mathematical modeling of antihypertensive therapy

  2022cites this paper
• Losartan

  2021cites this paper
• New Analytical Method for Simultaneous Analysis of Losartan and E-3174 by HPLC in Human Plasma: Application in Pharmaceutical Science

  2020cites this paper
• Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety

  2020cites this paper
• Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension.

  2017cites this paper
• Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension.

  2017cites this paper
• Treatment of Hypertension: Favourable Effect of the Twice-Daily Compared to the Once-Daily (Evening) Administration of Perindopril and Losartan

  2015cites this paper
• International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli

  2015cites this paper
• Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis.

  2014cites this paper
• Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan

  2013cites this paper
• Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan

  2013cites this paper
• A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol

  2013cites this paper
• Rationale for Fixed-Dose Combinations in the Treatment of Hypertension

  2012cites this paper
• Comparison of the effects of angiotensin II receptor antagonist monotherapy and combination therapy with a diuretic on cardiac function in spontaneously hypertensive rats

  2012cites this paper
• Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension.

  2010cites this paper
• The Possible Beneficial Effect of Angiotensin II Receptor Antagonist (Losartan) in Experimental- Hepatic Fibrosis in Albino Rats. Histological, Immunohistochemical and Biochemical Study

  2009cites this paper
• Influence of the angiotensin II receptor antagonist losartan on diuretic-induced metabolic effects in elderly hypertensive patients: comparison with a calcium channel blocker.

  2009cites this paper
• Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET--a call for more circumspection.

  2008cites this paper
• Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension.

  2008cites this paper
• Impact of Simvastatin and Losartan on Antiinflammatory Effect: In Vitro Study

  2007cites this paper
• Review: Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension?

  2005cites this paper
• Late onset renal failure from angiotensin blockade (LORFFAB): a prospective thirty-month Mayo Health System clinic experience.

  2005cites this paper
• New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia

  2005cites this paper
• Comparative Antihypertensive Efficacy of Angiotensin Receptor Blocker‐Based Treatment in African‐American and White Patients

  2005cites this paper
• Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring

  2005cites this paper
• Clinical Pharmacokinetics of Losartan

  2005cites this paper
• Uric acid: role in cardiovascular disease and effects of losartan

  2004cites this paper
• Hypokalemia and ST Elevation Induced by Angiotensin II Type 1 Receptor Blocker and Thiazide Diuretic Combination

  2004cites this paper
• Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension.

  2003cites this paper
• Evaluation of the 24 h effects of the angiotensin II receptor blockers: means to improve cardiovascular outcomes?

  2003cites this paper
• New therapeutic agents for hypertension.

  2003cites this paper
• The antiproteinuric effect of losartan is systemic blood pressure dependent.

  2003cites this paper
• A HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC ASSAY FOR THE DETERMINATION OF LOSARTAN IN PLASMA

  2003cites this paper
• Losartan titration versus diuretic combination in type 2 diabetic patients

  2002cites this paper
• Part 1. Uric acid and losartan

  2002cites this paper
• Trough-to-Peak Ratio, Smoothness Index, and Circadian Blood Pressure Profile After Treatment With Once-Daily Fixed Combination of Losartan 100 and Hydrochlorothiazide 25 in Essential Hypertension

  2002cites this paper
• A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).

  2002cites this paper
• Effects of GH replacement on 24‐h ambulatory blood pressure and its circadian rhythm in adult GH deficiency

  2002cites this paper
• Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension.

  2001cites this paper
• Angiotensin II Type 1 Receptor Blockers

  2001cites this paper
• Left Ventricular Hypertrophy With Exercise and ACE Gene Insertion/Deletion Polymorphism: A Randomized Controlled Trial With Losartan

  2001cites this paper
• Angiotensin II-receptor blockers: clinical relevance and therapeutic role.

  2001cites this paper
• Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension.

  2001cites this paper
• A randomised, placebo-controlled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension

  2001cites this paper
• New Competition in the Realm of Renin—Angiotensin Axis Inhibition; the Angiotensin II Receptor Antagonists in Congestive Heart Failure

  2001cites this paper
• Efficacy and safety of angiotensin receptor blockers: a review of losartan in essential hypertension

  2001cites this paper
• Effects of Losartan on the Renin-Angiotensin-Aldosterone System and Erythrocytosis in Patients with Chronic Obstructive Pulmonary Disease and Systemic Hypertension

  2001cites this paper
• Hemmer des Renin-Angiotensin-Systems

  2001cites this paper
• Burnier Angiotensin II Type 1 Receptor Blockers

  2001cites this paper
• Regression of left ventricular hypertrophy by AT1 receptor blockade in renal transplant recipients.

  2000cites this paper
• Pharmacologic, Pharmacokinetic, and Therapeutic Differences Among Angiotensin II Receptor Antagonists

  2000cites this paper
• A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators.

  2000cites this paper
• Comparison of the efficacy and safety of losartan (50–100 mg) with the T‐type calcium channel blocker mibefradil (50–100 mg) in mild to moderate hypertension

  2000cites this paper
• A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure

  2000cites this paper
• PRODUCT MONOGRAPH

  2000cites this paper
• SAFE AND EFFECTIVE MANAGEMENT OF HYPERTENSION WITH FIXED‐DOSE COMBINATION THERAPY: FOCUS ON LOSARTAN PLUS HYDROCHLOROTHIAZIDE

  2000cites this paper
• Tolerability and Antihypertensive Efficacy of Losartan vs Captopril in Patients with Mild to Moderate Hypertension and Impaired Renal Function

  2000cites this paper
• The Pharmacokinetics and Pharmacodynamics of Losartan in Continuous Ambulatory Peritoneal Dialysis

  2000cites this paper
• Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators.

  2000cites this paper
• A comparative review of the efficacy of antihypertensive agents on 24 h ambulatory blood pressure.

  2000cites this paper
• Long‐term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case‐control study

  2000cites this paper
• The angiotensin II-receptor antagonist losartan does not prevent hemodynamic or vascular tolerance to nitroglycerin.

  1999cites this paper
• Comparison of antihypertensive efficacy and tolerability of losartan and extended-release felodipine in patients with mild to moderate hypertension.

  1999cites this paper
• Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia.

  1999cites this paper
• Angiotensin receptor blockers: pharmacology and clinical significance.

  1999cites this paper
• Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension.

  1999cites this paper
• Angiotensin II receptor antagonists and hypertension.

  1999cites this paper
• Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection.

  1999cites this paper
• A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.

  1999cites this paper
• Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring

  1999cites this paper
• Wirkung von Candesartan cilexetil auf den Glukosestoffwechsel

  1999cites this paper
• Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin ii receptor antagonists in the treatment of hypertension

  1999cites this paper
• Unerwünschte Arzneimittelwirkungen und Wechselwirkungen von AT1-Rezeptorantagonisten

  1999cites this paper
• ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension

  1999cites this paper
• Effects of losartan on hypertension and left ventricular mass: a long-term study

  1998cites this paper
• Combination drug therapy in hypertension: a rational approach for the pharmacist.

  1998cites this paper
• Angiotensin II receptor antagonists and treatment of hypertension and renal disease

  1998cites this paper
• Angiotensin II receptor antagonists: what future?

  1998cites this paper
• Clinical Pharmacokinetics of Vasodilators

  1998cites this paper
• ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKADE: A NEW DEVELOPMENT IN CARDIOVASCULAR PHARMACOLOGY

  1998cites this paper
• [Angiotensin II AT1 receptor antagonists: clinical development and future perspectives].

  1998cites this paper
• A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Tasosartan Investigator's Group.

  1998cites this paper
• Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.

  1998cites this paper
• Clinical pharmacology of modern antihypertensive agents and their interaction with alpha-adrenoceptor antagonists.

  1998cites this paper
• Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes.

  1998cites this paper
• Evaluation of the Losartan in Hemodialysis (ELHE) Study.

  1998cites this paper
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial of Four Doses of Tasosartan in Patients With Essential Hypertension

  1998cites this paper
• Efficacy and Tolerability of Irbesartan, an Angiotensin II Receptor Antagonist, in Primary Hypertension

  1998cites this paper
• Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients

  1998cites this paper
• Pharmacokinetics of Intravenous and Oral Losartan in Patients with Heart Failure

  1998cites this paper
• The Clinical Effects of Losartan(Cozaar ® on Hypertensive Patients

  1998cites this paper
• [Renin-angiotensin-aldosterone system inhibition: pharmacologic rationale and evaluations of drug combinations].

  1998cites this paper
• Effects of Losartan and Diltiazem on Blood Pressure, Insulin Sensitivity, Lipid Profile and Microalbuminuria in Hypertensive Type 2 Diabetic Patients

  1998cites this paper
• Effects of candesartan cilexetil on glucose homeostasis. Multicenter Study Group.

  1998cites this paper
• Fixed low-dose drug combination for the treatment of hypertension.

  1998cites this paper
• Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on blood pressure and peripheral capillary microcirculation in patients with mild-to-moderate hypertension

  1998cites this paper
• Start of therapy with the angiotensin II antagonist losartan after immediate switch from pretreatment with an ACE inhibitor.

  1998cites this paper
• [Comparison between the effects of angiotensin-converting enzyme inhibitors and angiotensin II antagonists].

  1998cites this paper
• Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.

  1998cites this paper